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Predictive accuracy of the Framingham coronary risk score in
British men: prospective cohort study
Peter Brindle, Jonathan Emberson, Fiona Lampe, Mary Walker, Peter Whincup, Tom Fahey, Shah Ebrahim
Abstract
Objective To establish the predictive accuracy of the
Framingham risk score for coronary heart disease in a
representative British population.
Design Prospective cohort study.
Setting 24 towns in the United Kingdom.
Participants 6643 British men aged 40-59 years and free from
cardiovascular disease at entry into the British regional heart
study.
Main outcome measures Comparison of observed 10 year
coronary heart disease mortality and event rates with predicted
rates for each individual, using the relevant Framingham risk
equation.
Results Of 6643 men, 2.8% (95% confidence interval 2.4% to
3.2%) died from coronary heart disease compared with 4.1%
predicted (relative overestimation 47%, P < 0.0001). A fatal or
non-fatal coronary heart disease event occurred in 10.2% (9.5%
to 10.9%) of the men compared with 16.0% predicted (relative
overestimation 57%, P < 0.0001). These relative degrees of
overestimation were similar at all levels of coronary heart
disease risk, so that overestimation of absolute risk was greatest
for those at highest risk. A simple adjustment provided an
improved level of accuracy. In a “high risk score” approach,
most cases occur in the low risk group. In this case, 84% of the
deaths from coronary heart disease and non-fatal events
occurred in the 93% of men classified at low risk ( < 30% in 10
years) by the Framingham score.
Conclusion Guidelines for the primary prevention of coronary
heart disease advocate offering preventive measures to
individuals at high risk. Currently recommended risk scoring
methods derived from the Framingham study significantly
overestimate the absolute coronary risk assigned to individuals
in the United Kingdom.
Introduction
Coronary heart disease is a major cause of death and disability in
the developed world.1 Identification of people who are at high
risk of developing coronary heart disease but currently have no
symptoms has become an accepted method for the primary pre-
vention of coronary heart disease in many countries. The
national service framework for coronary heart disease in
England and Wales states that people whose estimated risk of
coronary heart disease based on a specified risk factor profile is
>30% over 10 years should be identified and offered appropri-
ate advice and treatment.2 European, American, and Canadian
guidelines also use predicted 10 year risk to identify people for
risk factor modification.3–6
It is recommended that risk assessment be performed using
one of several methods that combine values for different risk
factors to produce a quantitative risk estimate.7–9 These methods
use regression equations derived from a population sample of
the Framingham heart study and the Framingham offspring
study.10 Despite evidence that Framingham risk equations
systematically overestimate risk of coronary heart disease in
populations with lower coronary heart disease mortality, risk
scoring methods based on these equations have been
introduced widely.11–13 It remains unclear, however, whether the
Framingham risk score accurately predicts risk of coronary
heart disease in the British population.We assessed the ability of
the Framingham risk equations to predict death from coronary
heart disease and the combination of fatal and non-fatal coron-
ary heart disease events that is the outcome used in current
scoring methods, in a representative population of British men
over a 10 year period.7–9
Participants and methods
The Framingham studies
The risk assessment methods recommended for British and
European use are adapted from published equations derived
from 5573 men and women from the Framingham heart study
and the Framingham offspring study. People aged 30-74 and
free of cardiovascular disease were included, and risk estimates
for cardiovascular diseases were derived from around 12 years of
follow up. Equations were derived for six outcomes, two of which
we consider here: death from coronary heart disease, and all fatal
and non-fatal coronary heart disease events (box).10 14
The British regional heart study
The British regional heart study is a prospective study of 7735
men, aged 40-59 years at entry (1978-80), who were randomly
selected from the age and sex registers of one general practice in
each of 24 towns in the United Kingdom. The towns were
selected to represent the range of cardiovascular disease
mortality in the United Kingdom at the time.15 The response rate
was 78%, and participants have been followed up for cause spe-
cific mortality using the NHS central registers and for cardiovas-
cular morbidity through regular two yearly reviews of general
practice records, with fewer than 1% of participants lost to follow
up.16 For the purpose of our analysis, we chose the criteria used
to define pre-existing cardiovascular disease in the British
regional heart study to match those of the Framingham study as
closely as possible (table 1).17
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Statistical methods
Assessing the accuracy of the Framingham equation
Using the appropriate Framingham equations, we calculated the
risk of death from coronary heart disease and all coronary heart
disease events over a 10 year period for each of the men in the
British regional heart study who were initially free of cardiovas-
cular disease and had complete information on risk factors (see
box). We categorised the men into groups defined by quintiles of
Framingham risk, systolic blood pressure, total to high density
lipoprotein cholesterol ratio, and age. We compared the average
predicted event rates within each quintile for both end points
with the observed 10 year rates. The Hosmer Lemeshow test was
used to assess goodness of fit.18
Geographical variation
To assess any regional differences between observed and
predicted rates, we also categorised the men by region of
residence at baseline: Scotland, the north of England, the
Midlands and Wales, and the south of England.
Discrimination
To assess the performance of the screening test at identifying
individuals at “high risk,” we calculated the sensitivity and specifi-
city for risk score thresholds of >30% and >15% over 10 years.
Results
Of 7735 men recruited to the British heart regional study, 6942
(89.7%) were free of definite angina on the Rose angina
questionnaire and had no recall of a doctor diagnosis of cardio-
vascular disease and no electrocardiographic evidence of
definite myocardial infarction. Of these men, 6643 (95.7%) had
complete data on risk factors at baseline. Table 2 compares the
baseline characteristics of these men with those of the 2590 men
from the Framingham cohorts used in the derivation of the risk
equations.
Observed and predicted coronary heart disease mortality
When the coronary heart disease mortality equation (equation
B1 in box) was applied to each of the men in the British regional
heart study, the predicted number of deaths from coronary heart
disease within 10 years was 270 (4.1%). This compared with an
observed 183 deaths from coronary heart disease, giving a rate
of 2.8% (95% confidence interval 2.4% to 3.2%) over the first 10
years of follow up. Figure 1 displays predicted and observed
mortality from coronary heart disease across a range of risk lev-
els (according to the quintiles of Framingham risk, systolic blood
pressure, total to high density lipoprotein cholesterol, and age).
This relative over-prediction of mortality risk by 47% (P value for
goodness of fit < 0.0001) was similar at all risk levels (fig 1a), so
that over-prediction of absolute risk was greatest for people at
highest risk. Similarly, figures 1b-d show that significant overesti-
Framingham risk equations for coronary heart disease
death (B1) and coronary heart disease events (B2) in
men over 10 years
Step 1
For coronary heart disease mortality calculate*
= 11.2889 − 0.588×log(systolic blood
pressure) − 0.1367×smoking − 0.3448×log(total/high density
lipoprotein cholesterol)
− 0.1237×electrocardiographic left ventricular
hypertrophy − 0.944×log(age) − 0.0474×diabetes
= exp(2.9851 − 0.9142) (B1)
For coronary heart disease events calculate*
= 15.5303 − 0.9119×log(systolic blood
pressure) − 0.2767×smoking − 0.7181×log(total/high density
lipoprotein cholesterol)
− 0.5865×electrocardiographic left ventricular
hypertrophy − 1.4792×log(age) − 0.1759×diabetes
= exp( − 0.3155 − 0.2784×( − 4.4181)) (B2)
Step 2
For both equations calculate:
= (log(10) − )/ Length of follow up = 10 years
Step 3
The predicted probability is then given by:
p = 1 − exp(-exp(u))
*Variables smoking, electrocardiographic left ventricular hypertrophy, and
diabetes are set to 1 when present and 0 when absent. Systolic blood
pressure measured in mm Hg and age in years
Table 1 Risk factor and definitions of end points
Framingham British regional heart study
Exclusions History of stroke, transient ischaemia, intermittent claudication,
and cancer (other than basal cell carcinomas). Physician
assessed definite angina pectoris, myocardial infarction and
congestive cardiac failure. Definite electrocardiographic
evidence of myocardial infarction and coronary insufficiency.
Doubtful electrocardiographic evidence of myocardial infarction
Rose angina (definite grade I or II), self report of doctor
diagnosis of: coronary thrombosis, myocardial infarction, heart
attack, angina, or stroke. Definite electrocardiographic evidence
of myocardial infarction
Coronary heart disease mortality Panel review of death certificates using other available clinical
information including sudden death of presumed cardiac origin
Death with ischaemic heart disease as underlying cause
(codes 410-4; international classification of diseases, 9th
revision) including sudden death of presumed cardiac origin
Coronary heart disease event Coronary heart disease death, myocardial infarction, including
silent myocardial infarction by biennial electrocardiography,
doctor assessed angina and coronary insufficiency
Coronary heart disease death or any general practitioner report
of a new diagnosis of myocardial infarction or angina
(including possible cases)
Smoking Current or quit within past year Current or quit within past year
Diabetes Treatment with insulin or oral agents or having a fasting
glucose ≥140mg/dl
Recall of doctor diagnosis
Electrocardiographic evidence of left ventricular hypertrophy Definite Definite
Not Minnesota coded Minnesota coded
Systolic blood pressure Average of two measurements taken at same clinic visit Average of two measurements taken at same clinic visit
Diastolic blood pressure Average of two measurements taken at same clinic visit Average of two measurements taken at same clinic visit
Total cholesterol Abell-Kendell method Liebermann-Burchard method
High density lipoprotein cholesterol Determined after heparin-manganese precipitation Liebermann-Burchard method or enzymic procedures after
magnesium/phosphotungstate precipitation
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mation of risk occurs at all levels of the risk factors concerned,
apart from the lowest level of systolic blood pressure. For the
combined outcome of fatal coronary heart disease and any diag-
nosis of myocardial infarction or angina (equation B2 in box),
the observed number of events over 10 years was 677 (event rate
10.2%, 95% confidence interval 9.5% to 10.9%) compared with a
predicted 1062 (16.0%)—a relative over-prediction of 57% (P
value for goodness of fit < 0.0001; fig 2).
Geographical variation
Table 3 shows the observed versus predicted rates of coronary
heart disease mortality and all coronary events by region. Over-
prediction by the Framingham equations occurred in all regions
but was greatest in the south of England and the Midlands and
Wales where there was relatively lower mortality and morbidity
than in Scotland and the north of England.
Recalibration
As the relative over-prediction was about constant at all levels of
risk, it was possible for us to adjust the Framingham scores by
dividing the calculated score for each individual by the amount
of over-prediction. Recalibrated probabilities of death from cor-
onary heart disease were therefore obtained from the 10 year
predictions by dividing the final score by 1.47. For example, an
individual predicted to have a 5% chance of a fatal coronary
heart disease event within 10 years had a recalibrated risk of
3.4%. After making this correction, the predicted risk became
close to the observed rate at all levels of risk (fig 3a), as indicated
by a substantial decrease in the 2 statistic for goodness of fit from
30.2 to 3.4. Similarly, the risk equation for coronary heart disease
events was corrected to take into account the 57% relative over-
prediction by dividing the Framingham prediction by 1.57
(fig 3b). Again a large decrease was observed in the goodness of
fit statistic from 155.3 to 24.6.
Discrimination
When we applied the coronary event equation (see box) to the
baseline data in the British regional heart study, 444 men (6.7%)
had a predicted 10 year coronary heart disease event risk of
>30% (average predicted risk 36.2%), of whom only 106 (out of
the 677 men with a coronary heart disease event) actually had a
Table 2 Baseline characteristics of men in Framingham studies and British regional heart study without pre-existing cardiovascular disease and with
complete data on risk factors
Characteristic Framingham (n=2590)* British regional heart study (n=6643)
Period of baseline data collection 1968-75 1978-80
10 year coronary heart disease mortality (%) NA 2.8
10 year coronary heart disease event rate (%) 12.4 10.2
Age range (years) at baseline 30-74 40-59
Smoking (%) 40.7 41.9
Diabetes (%) 7.1 1.1
Electrocardiographic evidence of left ventricular hypertrophy (%) 1.1 2.6
Median (95% CI) blood pressure (mm Hg):
Systolic blood pressure 128 (109 to 168) 143 (115 to 182)
Diastolic blood pressure 82 (69 to 102) 81 (62 to 105)
Median ratio (95% CI) of total to high density lipoprotein
cholesterol
4.8 (2.9 to 8.0) 5.5 (3.5 to 8.6)
NA=not available.
*From Anderson et al.10
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coronary heart disease event within the following 10 years—a
sensitivity of 16% (106/677). The sensitivity increased to 75%
(509/677) when a 15% risk threshold was used, but this was at
the expense of a large drop in specificity from 94% (5628/5966)
to 55% (3258/5966) and a large increase in the proportion of
men classified as high risk (from 6.7% to 48.4%). Similar
estimates of sensitivity and specificity were obtained when using
these thresholds to identify individuals at high risk of coronary
heart disease death within 10 years.
When the recalibrated equation was used, those in the high
risk group identified by using the >30% threshold would now
constitute only 0.5% of the population and identify only 1.8%
(12/677) of the coronary heart disease events occurring within
10 years, so that preventive interventions restricted to this group
would have a limited population impact. If a >15% threshold
was used with the recalibrated equation, 17% of the population
would be classified as high risk, and 37% (249/677) of coronary
heart disease events would be identified. The specificities at the
30% or more and 15% or more thresholds using the recalibrated
equation would be 99.6% (5944/5966)and 85% (5055/5966),
respectively.
Discussion
The Framingham equations used in current risk scoring
methods over-predict the risk of mortality from coronary heart
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Table 3 Ten year predicted versus observed rates of coronary heart disease mortality and all coronary events by region
Region
Coronary heart disease deaths Coronary heart disease events
Predicted rate
(%)
Observed rate (%)
(95% CI)
Predicated over
observed
Predicted rate
(%)
Observed rate (%)
(95% CI)
Predicted over
observed
South of England (n=2086) 3.8 2.3 (1.7 to 3.1) 1.65 15.4 9.0 (7.8 to 10.3) 1.71
Midlands and Wales (n=942) 3.8 1.9 (1.2 to 3.1) 2.01 15.6 9.1 (7.4 to 11.2) 1.71
North of England (n=2783) 4.2 3.3 (2.7 to 4.1) 1.27 16.3 10.6 (9.5 to 11.8) 1.54
Scotland (n=832) 4.5 3.0 (2.0 to 4.5) 1.50 16.8 13.1 (10.9 to 15.6) 1.28
All (n=6643) 4.1 2.8 (2.4 to 3.2) 1.47 16.0 10.2 (9.5 to 10.9) 1.57
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disease and all fatal and non-fatal coronary heart disease events
by 47% and 57%, respectively, compared with observed events in
a representative sample of British men. The relative degree of
over-prediction was similar at all levels of individual risk.
Limitations of study
The Framingham study included the category “unrecognised
myocardial infarction” in the ascertainment of non-fatal
coronary heart disease events, therefore a potential source of
bias could exist. However, this seems to have had little effect, as
both fatal and all events were similarly overestimated. This is
probably because the definition of a coronary heart disease
event in the British regional heart study was broad, including all
possible cases of myocardial infarction and angina documented
in the medical records. Although coronary heart disease death is
a more accurately defined end point, there is still a possible
source of bias in the way the cause of death was identified. The
British regional heart study used death certificates and post-
mortem reports, whereas in the Framingham study the cause of
death documented on the certificate was verified by reviewing
autopsy data, hospital records, and records of the attending doc-
tor. However, coronary heart disease is an over-reported cause of
death on death certificates, so any bias would tend to result in our
analyses being conservative, underestimating the level of
over-prediction.19 Some minor differences are apparent in the
individuals excluded from both studies and in the use of a more
sensitive Framingham definition of diabetes. The numbers of
patients with diabetes, however, are small, and because the
unidentified predicted risk for such patients would be under-
estimated, any bias would again lead to our results being
conservative. A further limitation of our study is that its conclu-
sions cannot be assumed to apply to women, although the effect
of altering risk factors and the accuracy of models predicting
coronary heart disease are similar in both men and women and
therefore the findings are likely to be relevant to risk prediction
in women.12 20
Other studies
The Whickham (UK) study, conducted between 1972 and 1974
with a single follow up 20 years later, compared observed events
in 1700 men and women with rates predicted by a Framingham
equation.21 22 The observed and predicted event rates in the
higher risk population (coronary heart disease event rate greater
than 1.5% per year) were similar, but the Framingham equation
underestimated risk in those at lower risk. In the Whickham
study, the annual coronary heart disease event rate was 1.56%
compared with 1.02% for men in the British regional heart study.
This may reflect the true risk of the population from the north
east of England, or might be because the ascertainment of
coronary heart disease events was broad, including all
participants who had had minor electrocardiographic changes
on follow up and all deaths with any mention of ischaemic heart
disease.
A trial investigating the effectiveness of pravastatin in the pri-
mary prevention of coronary heart disease found a close agree-
ment between the observed coronary heart disease event rate in
the placebo group over 4.4 years and the value predicted from
the Framingham equation. Both the Scottish location and the
other inclusion criteria of the trial, however, led to the inclusion
of a group at particularly high absolute risk, with an annual cor-
onary heart disease event rate in the placebo group of 1.59%.23 In
German, Italian, and Danish studies, Framingham risk scores
with differing outcomes have been shown to overestimate risk by
up to 50%.12 13 24 A European based risk score has been devised to
address this.25 In a comparison of the British regional heart
study, the prospective cardiovascular Munster (PROCAM) heart
study, Dundee, and Framingham risk functions, no direct valida-
tion was possible because different end points were used and no
follow up data were collected.26
Explanations for different predicted and observed risk
The over-prediction of 10 year risk by the Framingham
equations in our analysis is likely to reflect a true difference in the
levels of risk between the two populations and is unlikely to be
due to over fitting of the Framingham data, as the number of risk
factors considered is modest compared with the number of
events observed.27 Coronary heart disease mortality in England
and Wales in 1980 was 30% lower than that in the United States
in 1970.28 The difference between this figure and the 47% over-
estimation found in our study may be due to differences between
national statistics and the study populations as well as the predic-
tive inaccuracy of the Framingham equation in the population
participating in the British regional heart study. Furthermore,
possible explanations for the differences in US and British mor-
tality may be better control of coronary risk factors and better
treatment of coronary heart disease experienced by the later
British cohort.
Risk functions derived from the Framingham study and oth-
ers are reasonably consistent at ranking individuals according to
their relative risk, and differences between the observed and pre-
dicted risk usually depend on the background risk of the popu-
lation to which the function is applied.12 24 We have shown inter-
regional variation suggesting that over-prediction is greater in
the regions of Britain with lower background coronary heart dis-
ease risk. Differences in observed and predicted risk have been
shown in different countries and between ethnic groups and may
be attributable to other risk factors that are not included in the
model.12 24 29
Implications
Overestimation of an individual’s true risk and the poor sensitiv-
ity of the recommended tool to identify and target individuals for
treatment have important implications for a national screening
test.2 An overestimated assessment of coronary heart disease risk
will undermine a patient’s ability to make an informed choice
about starting preventive treatment, may cause unnecessary
anxiety, and may affect life insurance premiums.30 If the patient’s
absolute risk is lower than predicted, the absolute benefits of
intervention will be smaller and the balance of risks and benefits
less favourable. Additionally, overestimation of risk prediction
will adversely affect direct prescribing costs as well as the costs of
drug monitoring and dealing with side effects.
The accuracy of risk estimates derived from cohort studies or
from randomised controlled trials are always open to the
criticism of being out of date compared with current morbidity
rates, owing to the delay between the collection of baseline data
and the reporting of incident events.31 If coronary heart disease
rates continue to fall, the discrepancy between predicted and
actual risk is likely to increase, as the decline is not entirely attrib-
utable to falls in the risk factors included in the Framingham
equation.32 Furthermore, fewer people will fall into the high risk
group, causing the proportion of coronary heart disease events
prevented by targeting only these individuals to be reduced.
We have shown that current risk scoring methods seem to
overestimate coronary heart disease risk and that a simple
adjustment can improve their predictive accuracy in the British
population. Nevertheless, further refinements are necessary
before the substantial variations in coronary heart disease risk
found between different regions and different ethnic groups,
socioeconomic status, and family history of coronary heart
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disease can be accommodated into an accurate and effective
treatment decision aid.
Baseline serum total cholesterol and high density lipoprotein cholesterol
were measured at the Wolfson Research Laboratories, Birmingham. The
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What is already known on this topic
Primary prevention of coronary heart disease involves
identifying patients at high risk and offering them lifelong
preventive treatment
Most risk assessment methods rely on equations derived
from the Framingham study
Evidence is conflicting as to the suitability of these
equations for British and other European populations
What this study adds
Recommended risk scoring methods overestimated
coronary risk in a representative British male population
This was similar at all levels of coronary heart disease risk
and could be reduced by a simple adjustment
Use of a predicted ≥ 30% coronary heart disease 10 year
event rate threshold to identify patients at high risk can fail
to identify most who go on to have a coronary heart disease
event over the following 10 years
Primary care
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